US 11,884,669 B1Granted

Pyrrolo[3,2-c][1,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors

AssigneeKing Faisal University

InventorsMichelyne Haroun, Christophe Tratrat

Life of this patent

Estimating the term…

Abstract

The pyrrolo[3,2-c][1,7]naphthyridine-2-carboxylic acid compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases. The described compounds have the formula I:

Claims18

Dependent claims

A compound having the formula I:

or a pharmaceutically acceptable salt, ester, stereoisomer, or solvate thereof, wherein:
R1 is selected from the group consisting of hydrogen, C1-C6 straight chained alkyl, and C1-C6 branched alkyl;
R2 is selected from the group consisting of consisting of —Ar, —NHAr, —NHCH2Ar, —NHCH2CH2Ar, —NHCOAr, —NHCOAr, —NHSO2Ar, —SO2Ar, —NHCH2CH2NHR5, —NHCH2CH2NR5R6, —NHCH2CH2CH2NHR5, —NHCH2CH2CH2NR5R6, —NHCOCH2CH2NHR5, —NHCOCH2CH2NR5R6, —NHCOCH2CH2CH2NHR5, —NHCOCH2CH2CH2NR5R6, —NHSO2CH2CH2NHR5, —NHSO2CH2CH2NR5R6, —NHSO2CH2CH2CH2NHR5, —NHSO2CH2CH2CH2NR5R6, —CH2Ar, —CH2CH2Ar, —COAr, —CH2CH2NHR5, —CH2CH2NR5R6, —CH2CH2CH2NHR5, —CH2CH2CH2NR5R6, —COCH2CH2NHR3, —COCH2CH2NR5R6, —COCH2CH2CH2NHR5, —COCH2CH2CH2NR5R6, —SO2CH2CH2NHR5, —SO2CH2CH2NR5R6, —SO2CH2CH2CH2NHR5, —SO2CH2CH2CH2NR5R6, C1-C6 straight chained alkyl, C1-C6 branched alkyl, C3-C6 cycloalkyl, halo-C1-C6 straight chained alkyl, halo-C1-C6 branched alkyl, halo-C3-C6 cycloalkyl, cyano-C1-C6 straight chained alkyl, cyano-C1-C6 branched alkyl, cyano-C3-C6 cycloalkyl;
Ar is an aryl ring or a 5 or 6 membered heteroaryl ring, either of the aryl ring or the heteroaryl ring being optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, —OH, —OR1, —NH2, —NHR3, —NR3R4, —CONH2, —CONHR3, —CONR3R4, —SO2NH2, —SO2NHR3, —SO2NR3R4, —NHCOR3, —NHCO2R3, —NHCONHR3, —NHSO2NHR3, —NHSO2R3, —COR3, —CO2R3, C1-C6 straight chained alkyl, C1-C6 branched alkyl, C3-C6 cycloalkyl, halo-C1-C6 straight chain alkyl, halo-C1-C6 branched alkyl, halo-C3-C6 cycloalkyl, cyano-C1-C6 straight chain alkyl, cyano-C1-C6 branched alkyl, and cyano-C3-C6 cycloalkyl;
R3 and R4 are each independently selected from the group consisting of hydrogen, C1-C6 straight chained alkyl, C1-C6 branched alkyl, C3-C6 cycloalkyl, halo-C1-C6 straight chain alkyl, halo-C1-C6 branched alkyl, halo-C3-C6 cycloalkyl, cyano-C1-C6 straight chain alkyl, cyano-C1-C6 branched alkyl, and cyano-C3-C6 cycloalkyl;
and
R5 and R6 are each independently selected from the group consisting of hydrogen, C1-C6 straight chained alkyl, C1-C6 branched alkyl, C3-C6 cycloalkyl, halo-C1-C6 straight chain alkyl, halo-C1-C6 branched alkyl, halo-C3-C6 cycloalkyl, cyano-C1-C6 straight chain alkyl, cyano-C1-C6 branched alkyl, and cyano-C3-C6 cycloalkyl, or wherein R5 and R6, taken together with a nitrogen atom to which they are attached, form a nitrogen-containing heterocycle, such nitrogen-containing heterocycle being optionally substituted with from one to three substituents independently selected from the group consisting of a straight or branched C1-C6 alkyl group, a halogen atom, a straight or branched C1-C6 alkoxy group, a straight or branched C1-C6 trihaloalkyl group, and a hydroxy group.

4 more elements

A pharmaceutically acceptable composition comprising a therapeutically effective amount of a compound selected from the group consisting of:

4-((3-chlorophenyl)amino)-1H-pyrrolo[3,2-c][1,7]naphthyridine-2-carboxylic acid (1);
4-(m-tolylamino)-1H-pyrrolo[3,2-c][1,7]naphthyridine-2-carboxylic acid (2);
4-((3-methoxyphenyl)amino)-1H-pyrrolo[3,2-c][1,7]naphthyridine-2-carboxylic acid (3);
4-((3-(dimethylamino)phenyl)amino)-1H-pyrrolo[3,2-c][1,7]naphthyridine-2-carboxylic acid (4);
4-((4-chlorophenyl)amino)-1H-pyrrolo[3,2-c][1,7]naphthyridine-2-carboxylic acid (5);
4-(p-tolylamino)-1H-pyrrolo[3,2-c][1,7]naphthyridine-2-carboxylic acid (6);
4-((4-methoxyphenyl)amino)-1H-pyrrolo[3,2-c][1,7]naphthyridine-2-carboxylic acid (7);
4-((4-(dimethylamino)phenyl)amino)-1H-pyrrolo[3,2-c][1,7]naphthyridine-2-carboxylic acid (8);
4-((3-isopropylphenyl)amino)-1H-pyrrolo[3,2-c][1,7]naphthyridine-2-carboxylic acid (9);
4-((3-(dimethylcarbamoyl)phenyl)amino)-1H-pyrrolo[3,2-c][1,7]naphthyridine-2-carboxylic acid (10);
4-((3-(N,N-dimethylsulfamoyl)phenyl)amino)-1H-pyrrolo[3,2-c][1,7]naphthyridine-2-carboxylic acid (11);
4-((2-methylpyridin-4-yl)amino)-1H-pyrrolo[3,2-c][1,7]naphthyridine-2-carboxylic acid (12);
4-((3-chlorobenzyl)amino)-1H-pyrrolo[3,2-c][1,7]naphthyridine-2-carboxylic acid (13);
4-((pyridin-3-ylmethyl)amino)-1H-pyrrolo[3,2-c][1,7]naphthyridine-2-carboxylic acid (14);
4-((3-(dimethylamino)propyl)amino)-1H-pyrrolo[3,2-c][1,7]naphthyridine-2-carboxylic acid (15);
4-((3-(4-methylpiperazin-1-yl)propyl)amino)-1H-pyrrolo[3,2-c][1,7]naphthyridine-2-carboxylic acid (16);
and a pharmaceutically acceptable salt, ester, stereoisomer, or solvate thereof;
and
a pharmaceutically acceptable carrier.

16 more elements

Dependencies are inferred from the claim text.

patentgrep

Loading patent…

Abstract

A compound having the formula I:

or a pharmaceutically acceptable salt, ester, stereoisomer, or solvate thereof, wherein:
R1 is selected from the group consisting of hydrogen, C1-C6 straight chained alkyl, and C1-C6 branched alkyl;
R2 is selected from the group consisting of consisting of —Ar, —NHAr, —NHCH2Ar, —NHCH2CH2Ar, —NHCOAr, —NHCOAr, —NHSO2Ar, —SO2Ar, —NHCH2CH2NHR5, —NHCH2CH2NR5R6, —NHCH2CH2CH2NHR5, —NHCH2CH2CH2NR5R6, —NHCOCH2CH2NHR5, —NHCOCH2CH2NR5R6, —NHCOCH2CH2CH2NHR5, —NHCOCH2CH2CH2NR5R6, —NHSO2CH2CH2NHR5, —NHSO2CH2CH2NR5R6, —NHSO2CH2CH2CH2NHR5, —NHSO2CH2CH2CH2NR5R6, —CH2Ar, —CH2CH2Ar, —COAr, —CH2CH2NHR5, —CH2CH2NR5R6, —CH2CH2CH2NHR5, —CH2CH2CH2NR5R6, —COCH2CH2NHR3, —COCH2CH2NR5R6, —COCH2CH2CH2NHR5, —COCH2CH2CH2NR5R6, —SO2CH2CH2NHR5, —SO2CH2CH2NR5R6, —SO2CH2CH2CH2NHR5, —SO2CH2CH2CH2NR5R6, C1-C6 straight chained alkyl, C1-C6 branched alkyl, C3-C6 cycloalkyl, halo-C1-C6 straight chained alkyl, halo-C1-C6 branched alkyl, halo-C3-C6 cycloalkyl, cyano-C1-C6 straight chained alkyl, cyano-C1-C6 branched alkyl, cyano-C3-C6 cycloalkyl;
Ar is an aryl ring or a 5 or 6 membered heteroaryl ring, either of the aryl ring or the heteroaryl ring being optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, —OH, —OR1, —NH2, —NHR3, —NR3R4, —CONH2, —CONHR3, —CONR3R4, —SO2NH2, —SO2NHR3, —SO2NR3R4, —NHCOR3, —NHCO2R3, —NHCONHR3, —NHSO2NHR3, —NHSO2R3, —COR3, —CO2R3, C1-C6 straight chained alkyl, C1-C6 branched alkyl, C3-C6 cycloalkyl, halo-C1-C6 straight chain alkyl, halo-C1-C6 branched alkyl, halo-C3-C6 cycloalkyl, cyano-C1-C6 straight chain alkyl, cyano-C1-C6 branched alkyl, and cyano-C3-C6 cycloalkyl;
R3 and R4 are each independently selected from the group consisting of hydrogen, C1-C6 straight chained alkyl, C1-C6 branched alkyl, C3-C6 cycloalkyl, halo-C1-C6 straight chain alkyl, halo-C1-C6 branched alkyl, halo-C3-C6 cycloalkyl, cyano-C1-C6 straight chain alkyl, cyano-C1-C6 branched alkyl, and cyano-C3-C6 cycloalkyl;
and
R5 and R6 are each independently selected from the group consisting of hydrogen, C1-C6 straight chained alkyl, C1-C6 branched alkyl, C3-C6 cycloalkyl, halo-C1-C6 straight chain alkyl, halo-C1-C6 branched alkyl, halo-C3-C6 cycloalkyl, cyano-C1-C6 straight chain alkyl, cyano-C1-C6 branched alkyl, and cyano-C3-C6 cycloalkyl, or wherein R5 and R6, taken together with a nitrogen atom to which they are attached, form a nitrogen-containing heterocycle, such nitrogen-containing heterocycle being optionally substituted with from one to three substituents independently selected from the group consisting of a straight or branched C1-C6 alkyl group, a halogen atom, a straight or branched C1-C6 alkoxy group, a straight or branched C1-C6 trihaloalkyl group, and a hydroxy group.

4 more elements